Valcyte For Oral Solution

  • Viral infections

Valcyte For Oral Solution Generic Name & Formulations

General Description

Valganciclovir (as HCl) (prodrug of ganciclovir) 50mg/mL; pwd for reconstitution; tutti-frutti flavor.

Pharmacological Class

Nucleoside analogue.

See Also

How Supplied

Tabs—60; Soln—100mL (after constitution)


Generic Availability


Valcyte For Oral Solution Indications


Prevention of CMV disease in kidney transplant patients (4mos-16yrs old) and heart transplant patients (1mo-16yrs old) at high risk.

Valcyte For Oral Solution Dosage and Administration


Use tablet form.


Take with food once daily. Dose (mg)= 7 x BSA x Creatinine Clearance (if calculated Schwartz CrCl >150mL/min/1.73m2, then use max value of 150mL/min/1.73m2 in equation). Kidney transplant: <4mos: not recommended; ≥4mos: start within 10 days of transplantation until 200 days post-op. Heart transplant: <1mo: not recommended; ≥1mo: start within 10 days of transplantation until 100 days post-op. Round calculated dose to the nearest 10mg increment; max 900mg.

Valcyte For Oral Solution Contraindications


Ganciclovir allergy.

Valcyte For Oral Solution Boxed Warnings

Boxed Warning

Hematologic toxicity. Impairment of fertility. Fetal toxicity. Mutagenesis and carcinogenesis.

Valcyte For Oral Solution Warnings/Precautions


Risk of hematologic toxicity; monitor CBCs and platelets frequently esp. in infants, patients with renal dysfunction, history of leukopenia with ganciclovir or other nucleoside analogues, baseline ANC <1000cells/microliter. ANC <500cells/microliter, hemoglobin <8g/dL, platelets <25,000cells/microliter: not recommended. Pre-existing cytopenias or history of cytopenic reactions to other drugs, chemicals, or irradiation. Potential to cause impairment of fertility, fetal toxicity, cancer. Renal impairment. Monitor ophthalmic and renal function. Maintain adequate hydration. Avoid direct contact with broken tabs, powder, oral soln with skin or mucous membranes. Do not substitute on a mg-per-mg basis for ganciclovir. Elderly. Pregnancy: exclude status prior to initiation. Use effective contraception during and for at least 30 days (females) or 90 days (males) after treatment. Nursing mothers: not recommended.

Valcyte For Oral Solution Pharmacokinetics

See Literature

Valcyte For Oral Solution Interactions


Increased risk of seizures with imipenem-cilastatin; not recommended. Concomitant cyclosporine, amphotericin B: monitor renal function. May be potentiated by probenecid; reduce valganciclovir dose. May potentiate mycophenolate mofetil (MMF) metabolites or be potentiated by MMF in patients with renal impairment (monitor). Caution with nephrotoxic or myelosuppressive drugs (eg, adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/sulfamethoxazole, vincas, zidovudine). Monitor for toxicity with didanosine.

Valcyte For Oral Solution Adverse Reactions

Adverse Reactions

Diarrhea, pyrexia, fatigue, nausea, tremor, neutropenia, anemia, leukopenia, thrombocytopenia, headache, insomnia, UTI, vomiting; children: also upper RTI.

Valcyte For Oral Solution Clinical Trials

See Literature

Valcyte For Oral Solution Note

Not Applicable

Valcyte For Oral Solution Patient Counseling

See Literature